XtalPi and Yichang Humanwell Pharmaceutical Enter AI Platform Licensing Agreement: PatSight Empowers Innovative Drug R&D

Click the image to view conference details.↑↑↑

XtalPi recently announced that it has established a licensing partnership with Yichang Humanwell Pharmaceutical Co., Ltd. ("Yichang Humanwell") for its PatSight platform.Jointly Address the Efficiency Bottleneck in Patent Data Analysis for Drug Development. According to the cooperationYichang Humanwell will fully apply the PatSight platform, deeply integrating its "AI-driven global drug patent data analysis" capability into the R&D process to systematically enhance the efficiency and quality of patent mining and layout, promoting the intelligent upgrade of R&D.

Dr. Huang Mengting, Head of Yichang Humanwell AI Intelligent Drug PlatformIt was pointed out that the introduction of XtalPi's PatSight platform is a key step for Yichang Humanwell Pharmaceutical Co., Ltd. to build a data-driven R&D system. The platform integrates OCR, molecular graph recognition, and large language model technologies, enabling "one-click analysis" of global drug patent intelligence. It can also seamlessly connect with XtalPi’s MoIValley platform for in-depth SAR analysis. This provides a powerful tool for systematically exploring chemical space and quickly identifying advantageous molecular fragments, significantly enhancing Yichang Humanwell's innovation efficiency on cutting-edge targets and the quality of its patent layout, laying a solid foundation for future market competition.

Chen Yongpan, Head of XtalPi's Digital Intelligence DivisionXtalPi stated that the birth of PatSight stems from the company’s in-depth research and scenario-focused exploration into the pain points of patent data processing in the drug R&D field. XtalPi consistently concentrates on the core needs of researchers in real-world work, using technology to break through efficiency bottlenecks. In the future, XtalPi will continue to invest in the iterative upgrading of its R&D platform, introducing high-quality products with functions more aligned with industry realities and performance that is more precise and efficient, continuously addressing customer challenges and accelerating the implementation of their innovative R&D achievements.

PatSight is an AI patent data mining tool independently developed by XtalPi. Integrated with large language models, OCR, molecular graph recognition, and other technologies, it can automatically extract key information such as compound numbers, structures, and activity values from patents. It also supports importing this data into its MolValley platform for SAR analysis. Its core functions include one-click parsing of global pharmaceutical patent data, automatic integration of structural and activity data, and high-precision molecular structure recognition. It supports high-frequency fragment analysis for rapid identification of key molecules, molecular property calculations, and ADMET property predictions. In terms of efficiency, PatSight can reduce the traditional manual literature extraction time from several days or weeks to 1 hour, with an accuracy rate of 95%-97% for compound and activity data recognition, significantly shortening the R&D cycle.

*This WeChat Official Account remains neutral on all original and reproduced content, statements, and viewpoint judgments. The shared content is for non-commercial purposes only. If any reproduced works or images have incorrect author source markings or involve infringement, original authors are kindly reminded to contact the editor for removal.

*Editorial Responsibility| Mu Yang

*Reprint Authorization | Teacher Zhang 17551939537(WeChat same number))

*Business Cooperation | LiuTeacher13262726197(WeChat same number)